Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.
Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.
Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a significant advancement in its patent strategy. The U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application number 16/076,026. This patent will extend intellectual property protection for the company's Allocetra™ therapy in combination with CAR T-cell therapy until at least 2036. Allocetra™ is designed to reprogram macrophages, potentially addressing unmet medical needs in diseases like solid cancers and sepsis. The patent is expected to be formally issued in 2023, enhancing the company's position in the competitive field of immunotherapy.
FAQ
What is the current stock price of Enlivex Therapeutics (ENLV)?
What is the market cap of Enlivex Therapeutics (ENLV)?
